MARFANS: Biological Collection for Marfan and Related Syndromes

Sponsor
University Hospital, Toulouse (Other)
Overall Status
Recruiting
CT.gov ID
NCT04970459
Collaborator
(none)
300
1
115
2.6

Study Details

Study Description

Brief Summary

The present study will establish a collection of biological samples from Marfan patients or with associated diseases to be used for research purposes only, with due respect for confidentiality.

Condition or Disease Intervention/Treatment Phase
  • Biological: collection of samples of blood and urine

Detailed Description

Marfan syndrome is an autosomal dominant disease (incidence 1/5000) characterized by ocular, cardiac and skeletal abnormalities. More recently, a decrease in fat and muscle mass has been demonstrated, associated with a decrease in exercise endurance, causing a significant deterioration in the quality of life. Little is known about the pathophysiology of these symptoms. Patients with Marfan syndrome or related diseases are followed at the children's hospital as part of the Rare Diseases Reference Centre (CRMR) for Marfan syndrome at the Toulouse University Hospital. During regular check-up visits, an extra sample of blood and urine will be collected and stored for research utilisation with the patient's consent. The ultimate objective of this collection is to provide available biological resources to facilitate the development of subsequent studies aimed at better characterizing the multisystemic disorders in Marfan syndrome, to understand the pathophysiology of the disease, and to identify biological factors that predict the severity and progression of the disease. The possibility of having systematically collected biological resources will make it possible to answer certain questions more quickly depending on the progress of research.

Study Design

Study Type:
Observational
Anticipated Enrollment :
300 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Constitution of a Biological Collection to Study the Pathophysiology in Marfan Syndrome and Related Syndromes and to Identify Predictive Factors of Disease Progression
Actual Study Start Date :
Jan 7, 2022
Anticipated Primary Completion Date :
Aug 7, 2026
Anticipated Study Completion Date :
Aug 7, 2031

Arms and Interventions

Arm Intervention/Treatment
Patients with Marfan syndrome or related syndromes

Children aged at least 3 years old or adult with Marfan syndrome or related syndromes

Biological: collection of samples of blood and urine
extra samples of blood and urine will be collected and stored for research utilisation

Outcome Measures

Primary Outcome Measures

  1. Constitution of a biological collection from patients with Marfan or related syndromes. [Day 0]

    extra sample of blood and urine will be collected

  2. Constitution of a biological collection from patients with Marfan or related syndromes. Collection of samples at inclusion. [during the intervention/procedure/surgery]

    extra sample of blood and urine will be collected

Eligibility Criteria

Criteria

Ages Eligible for Study:
3 Years to 99 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Children aged at least 3 years old or adult with Marfan syndrome or related syndromes

  • Patients affiliated to or beneficiaries of a social security scheme

  • Patients able to receive information on the progress of the study and understand the information form to participate in the study. That implies to master the French language and not to be subject to a restriction of rights by the judicial authorities

  • Patients or legal representative who have given their consent to participate in the study (expression of no objection)

Exclusion Criteria:
  • Patients subject to a legal protection measure (guardianship, curators, or safeguard of justice)

  • Pregnant or breastfeeding women

Contacts and Locations

Locations

Site City State Country Postal Code
1 Purpan University Hospital Toulouse France 31059

Sponsors and Collaborators

  • University Hospital, Toulouse

Investigators

  • Principal Investigator: Thomas Edouard, MD, University Hospital, Toulouse

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University Hospital, Toulouse
ClinicalTrials.gov Identifier:
NCT04970459
Other Study ID Numbers:
  • RC31/21/0178
First Posted:
Jul 21, 2021
Last Update Posted:
Apr 1, 2022
Last Verified:
Mar 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University Hospital, Toulouse
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 1, 2022